Science: Cancer Vaccine on the Horizon
Society | April 8, 2005, FridayA pioneering vaccine against the virus that causes cervical cancer and genital warts has been proved highly effective, according a recent scientific report.
The vaccine, produced by the drug company Merck & Co., was found to cut dramatically the infection rate of human papillomavirus (HPV), the cause of cervical cancer and genital warts, for both by 90% in a small-scale trial.
Gardasil, which could reach the market in 2006, is designed to protect women against four strains of the human papillomavirus (HPV).
Cervical cancer affects some 470,000 women a year and survival chances are good if the disease is detected and treated early.
The findings, published in the The Lancet Oncology, put pharmaceutical giants Merck & Co Inc ahead in the race to market the world's first anti-cancer vaccine.
The vaccine, produced by the drug company Merck & Co., was found to cut dramatically the infection rate of human papillomavirus (HPV), the cause of cervical cancer and genital warts, for both by 90% in a small-scale trial.
Gardasil, which could reach the market in 2006, is designed to protect women against four strains of the human papillomavirus (HPV).
Cervical cancer affects some 470,000 women a year and survival chances are good if the disease is detected and treated early.
The findings, published in the The Lancet Oncology, put pharmaceutical giants Merck & Co Inc ahead in the race to market the world's first anti-cancer vaccine.
» Subscribe to receive alerts by email for any of these keywords.
Share:
